The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...

This article aims to share how to build an effective healthcare content strategy that boosts online patient engagement and ...

Shares in Metsera shot up nearly 20% to more than $72 after news of the renewed bidding war emerged, raising its market ...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...

The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...

That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Today, POA Pharma is headquartered in Copenhagen, with additional facilities located across the Nordics and Germany. Galen ...

France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve patient outcomes in a phase 3 study, which has now been terminated. Genfit ...

After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the ...

But once a cancer has been detected, the ability to quickly specify exactly which treatment will work is set to have a transformative impact upon oncology, upon the wider world of medicine, and upon ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...